[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017004765A - Formulacion inhalable. - Google Patents

Formulacion inhalable.

Info

Publication number
MX2017004765A
MX2017004765A MX2017004765A MX2017004765A MX2017004765A MX 2017004765 A MX2017004765 A MX 2017004765A MX 2017004765 A MX2017004765 A MX 2017004765A MX 2017004765 A MX2017004765 A MX 2017004765A MX 2017004765 A MX2017004765 A MX 2017004765A
Authority
MX
Mexico
Prior art keywords
inhalable formulation
active pharmaceutical
pharmaceutical ingredient
propellant
inhalable
Prior art date
Application number
MX2017004765A
Other languages
English (en)
Inventor
Dalvi Mukul
Mccabe Jacquelyn
Original Assignee
Teva Branded Pharmaceutical Products R&D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Branded Pharmaceutical Products R&D Inc filed Critical Teva Branded Pharmaceutical Products R&D Inc
Publication of MX2017004765A publication Critical patent/MX2017004765A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Esta invención proporciona un proceso para la preparación de un ingrediente farmacéutico activo inhalable que comprende las etapas de calentar una suspensión de un ingrediente farmacéutico activo en un propelente licuado en un recipiente, la evaporación del propelente y recoger el polvo resultante.
MX2017004765A 2014-10-16 2015-10-16 Formulacion inhalable. MX2017004765A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064684P 2014-10-16 2014-10-16
PCT/US2015/055916 WO2016061445A1 (en) 2014-10-16 2015-10-16 Inhalable formulation

Publications (1)

Publication Number Publication Date
MX2017004765A true MX2017004765A (es) 2017-07-27

Family

ID=54361199

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004765A MX2017004765A (es) 2014-10-16 2015-10-16 Formulacion inhalable.

Country Status (15)

Country Link
US (1) US10653704B2 (es)
EP (1) EP3206667A1 (es)
JP (1) JP6653323B2 (es)
KR (1) KR20170070151A (es)
CN (1) CN107106515A (es)
AR (1) AR102304A1 (es)
AU (1) AU2015331912A1 (es)
BR (1) BR112017007589A2 (es)
CA (1) CA2963143A1 (es)
CO (1) CO2017004789A2 (es)
EA (1) EA201790832A1 (es)
IL (1) IL251664A0 (es)
MX (1) MX2017004765A (es)
PE (1) PE20170919A1 (es)
WO (1) WO2016061445A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
NZ246046A (en) 1991-12-12 1995-12-21 Glaxo Group Ltd Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
DE10043509A1 (de) 2000-09-01 2002-03-14 Asta Medica Ag Feste Peptidzubereitungen für die Inhalation und deren Herstellung
SE0004750D0 (sv) 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
AU2003244451A1 (en) * 2002-02-04 2003-09-02 Glaxo Group Limited Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
CN100589849C (zh) 2004-02-24 2010-02-17 微计量技术有限公司 基于合成射流的药物输送方法和装置
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
US8196576B2 (en) 2007-02-28 2012-06-12 Microdose Therapeutx, Inc. Inhaler
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PE20170690A1 (es) * 2014-10-16 2017-05-25 Teva Branded Pharmaceutical Products Randd Inc Formulacion de polvo seco

Also Published As

Publication number Publication date
EA201790832A1 (ru) 2017-09-29
US20170239269A1 (en) 2017-08-24
EP3206667A1 (en) 2017-08-23
WO2016061445A1 (en) 2016-04-21
JP6653323B2 (ja) 2020-02-26
BR112017007589A2 (pt) 2018-01-30
KR20170070151A (ko) 2017-06-21
PE20170919A1 (es) 2017-07-12
JP2017534611A (ja) 2017-11-24
IL251664A0 (en) 2017-06-29
CA2963143A1 (en) 2016-04-21
CO2017004789A2 (es) 2017-09-20
CN107106515A (zh) 2017-08-29
US10653704B2 (en) 2020-05-19
AU2015331912A1 (en) 2017-05-25
AR102304A1 (es) 2017-02-15

Similar Documents

Publication Publication Date Title
IL254353B (en) A vaporizing capsule for the vaporization of an active ingredient
PT3674298T (pt) Indazóis substituídos, métodos para a sua produção, preparações farmacêuticas que contêm os mesmos e sua utilização para produção de medicamentos
EP3097998A4 (en) Powder material of solid solution of nitrogen in titanium, titanium material, and process for producing powder material of solid solution of nitrogen in titanium
MX2018002627A (es) Metodo de cristalizacion y biodisponibilidad.
EP3180118A4 (en) Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients
PH12016501841A1 (en) Immunosuppressant formulation
IL272684A (en) Exosomes for specific delivery of a target and methods for its preparation and delivery
IL271852A (en) Solid powder supplements containing quercetin, a process for their preparation and their formulations
PH12018501023A1 (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
MY197524A (en) System of multiple bags and method for the preparation of hemocomponents
EP3560518A4 (en) COMPLEX FOR ADMINISTRATION AND STABILIZATION OF MEDICINAL PRODUCTS AND METHOD FOR MANUFACTURING THEREOF
GB2528421A (en) Methods and processes for application of drug delivery polymeric coatings
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
IN2014CH00840A (es)
EP3158998A4 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
EP3560918A4 (en) TRIAZOLE DERIVATIVE FROM THE CONDENSED CYCLE AZACYCLOBUTYL GROUP, PREPARATION METHOD THEREOF AND USE IN MEDICINE
MX2017004765A (es) Formulacion inhalable.
PL2996675T3 (pl) Formulacja farmaceutyczna, sposób wytwarzania formulacji farmaceutycznej i roztwór do infuzji oraz ich zastosowanie jako wyrobu medycznego i/lub leku
IN2014DE00111A (es)
MX2017003653A (es) Metodo para acondicionar un dianhidrohexitol, disolucion acuosa de dianhidrohexitol acondicionado, y usos de la misma.
GB201414271D0 (en) Composition for delivery of an active pharmaceutical substance and method of preparing same
IN2014CH01890A (es)